2w
Did you know? Dual bronchodilation with a LAMA/LABA combination produces greater improvements in lung function and symptom control than either agent alone in moderate-to-severe COPD. Tiotropium/olodaterol achieves sustained 24-hour bronchodilation, potentially reducing exacerbation frequency and improving exercise tolerance compared to monotherapy approaches.
At what disease stage do you typically escalate from monotherapy to dual bronchodilation in your COPD patients?
At what disease stage do you typically escalate from monotherapy to dual bronchodilation in your COPD patients?
-
JOEL WASHINSKY2wWorsening of PFT and increase in exacerbations.
-
Kevin Glass2moAt this point I am typically initiating treatment with a LAMA/LABA at any disease stage. I only occasionally start with monotherapy. I have a low threshold to escalate to triple therapy if there are ongoing daily symptoms or exacerbations.
-
SHABNAM SACHDEVA2moI usually start patients on dual bronchodilators if patients have moderate to severe COPD and move to a triple therapy if there is an exacerbation on dual therapy.
-
SACHINKUMAR PANCHAL2moAt what point in the disease course do you typically escalate from monotherapy to dual bronchodilation for patients with Chronic Obstructive Pulmonary Disease? Are symptom burden, exacerbation history, activity limitation, lung function measures, or other clinical factors the primary drivers of your decision to initiate a LAMA/LABA combination such as Tiotropium/Olodaterol?
-
BRETT NILE2moWill do that at any stage especially if there are symptoms or exacerbations
-
Terry Cheung2mousually at the start of it with moderate COPD or severe COPD patients I will go to dual or triple inhalers now